Acadian Asset Management’s Artiva Biotherapeutics ARTV Stock Holding History

Acadian Asset Management’s Portfolio ARTV Stock Details ARTV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$221K	Buy	+22,940	New	+$209K	﹤0.01%	1620

Other funds holding ARTV

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

Acadian Asset Management's ARTV Position: Q2 2026 in Review

Acadian Asset Management opened a new position in Artiva Biotherapeutics (ARTV) in Q2 2026: 22,940 shares worth $221K. The stake represents ﹤0.01% of the portfolio and ranks #1620 among its holdings.

72 funds tracked by Wall St. Rank hold ARTV as of Q2 2026.

Acadian Asset Management held 22,940 shares of Artiva Biotherapeutics worth $221K as of Q2 2026.
Artiva Biotherapeutics was a new Acadian Asset Management position in Q2 2026.
Artiva Biotherapeutics made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #1620 holding.
72 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.